tiprankstipranks
Celldex Therapeutics (CH:TCE1)
NASDAQ:TCE1

Celldex (TCE1) Stock Statistics & Valuation Metrics

0 Followers

Total Valuation

Celldex has a market cap or net worth of CHF2.48B. The enterprise value is $2.16B.
Market CapCHF2.48B
Enterprise Value$2.16B

Share Statistics

Celldex has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding
Owned by Insiders0.30%
Owned by Institutions1.41%

Financial Efficiency

Celldex’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -53.87%.
Return on Equity (ROE)-0.49
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-53.87%
Return on Capital Employed (ROCE)-0.54
Revenue Per Employee8.06K
Profits Per Employee-1.39M
Employee Count186
Asset Turnover<0.01
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Celldex is ―. Celldex’s PEG ratio is -0.12.
PE Ratio
PS Ratio1204.09
PB Ratio3.43
Price to Fair Value3.43
Price to FCF-8.45
Price to Operating Cash Flow-11.72
PEG Ratio-0.12

Income Statement

In the last 12 months, Celldex had revenue of 1.50M and earned -258.80M in profits. Earnings per share was -3.90.
Revenue1.50M
Gross Profit1.50M
Operating Income-287.40M
Pretax Income-258.80M
Net Income-258.80M
EBITDA-255.42M
Earnings Per Share (EPS)-3.90

Cash Flow

In the last 12 months, operating cash flow was -222.16M and capital expenditures -3.80M, giving a free cash flow of -225.96M billion.
Operating Cash Flow-222.16M
Free Cash Flow-225.96M
Free Cash Flow per Share-10.00T>

Dividends & Yields

Celldex pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta5.57
52-Week Price Change
50-Day Moving Average
200-Day Moving Average
Relative Strength Index (RSI)
Average Volume (3m)

Important Dates

Celldex upcoming earnings date is Aug 6, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date

Financial Position

Celldex as a current ratio of 10.49, with Debt / Equity ratio of 0.42%
Current Ratio10.49
Quick Ratio10.49
Debt to Market Cap0.00
Net Debt to EBITDA0.10
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Celldex has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Celldex EV to EBITDA ratio is -6.97, with an EV/FCF ratio of -8.33.
EV to Sales1.19K
EV to EBITDA-6.97
EV to Free Cash Flow-8.33
EV to Operating Cash Flow-8.44

Balance Sheet

Celldex has CHF451.46M in cash and marketable securities with CHF1.91M in debt, giving a net cash position of CHF449.55M billion.
Cash & Marketable SecuritiesCHF451.46M
Total DebtCHF1.91M
Net CashCHF449.55M
Net Cash Per ShareCHF10.00T>
Tangible Book Value Per ShareCHF7.52

Margins

Gross margin is -14287.93%, with operating margin of -19160.00%, and net profit margin of -17253.33%.
Gross Margin-14287.93%
Operating Margin-19160.00%
Pretax Margin-17253.33%
Net Profit Margin-17253.33%
EBITDA Margin-17028.00%
EBIT Margin-17253.33%

Analyst Forecast

The average price target for Celldex is CHF41.09, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetCHF41.09
Price Target Upside― Downside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast
EPS Growth Forecast

Scores

Smart Score9
AI Score